Cetuximab (Erbitux)

Cetuximab is a targeted cancer therapy given by IV infusion that blocks the epidermal growth factor receptor (EGFR), a protein that helps some cancer cells grow and divide. It is approved for certain head and neck cancers and metastatic colorectal cancers with specific tumor genetics, and has been studied in non-small cell lung cancer.

Origin

Cetuximab was developed in the 1980s–1990s from a chimeric (part mouse, part human) antibody known as C225 and received FDA approval in 2004 under the brand name Erbitux, marketed by ImClone, Bristol-Myers Squibb, and Eli Lilly. Its generic name follows the World Health Organization naming system for monoclonal antibodies: the "-ximab" ending signals a chimeric monoclonal antibody.

Significance in Asbestos Context

Patients with asbestos-related cancers may encounter cetuximab as part of treatment for asbestos-linked lung cancer or, less commonly, in clinical trials for mesothelioma, since some mesothelioma tumors overexpress EGFR. It is not a standard front-line treatment for mesothelioma, and its use in lung cancer depends on tumor type, EGFR status, and what other therapies (chemotherapy, immunotherapy, radiation) are being given. Documentation of the specific cancer diagnosis, tumor testing results, and full treatment history, including drugs like cetuximab and their side effects, becomes part of the medical record that supports both medical decision-making and any legal claim related to asbestos exposure.

Example Sentence

After her asbestos-related lung cancer progressed on initial chemotherapy, the oncologist discussed adding cetuximab (Erbitux) based on her tumor's EGFR expression.

Related Terms

EGFR (Epidermal Growth Factor Receptor), Monoclonal Antibody, Non-Small Cell Lung Cancer, Targeted Therapy, Mesothelioma, Chemotherapy

Notes

• Ask your oncologist whether your tumor has been tested for EGFR expression or mutations, and whether cetuximab is being considered as part of a standard regimen or a clinical trial.
• Watch for and report the characteristic acne-like skin rash, dry skin, nail changes, infusion reactions, and low blood magnesium. These are common with cetuximab and often require dose adjustments or supportive care.
• Keep copies of infusion records, pathology and biomarker reports, and notes about response and side effects; these documents matter both for ongoing care and for any asbestos-related legal claim that needs to show the course and cost of treatment.